Irinotecanhydrochlorid 3 H2o Kelix Bio (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer and related metastatic disease.

• Colorectal cancer: improves overall survival when used in combination chemotherapy.
• Metastatic colorectal cancer: part of standard first‑line regimens for advanced disease.
• Recurrent colorectal cancer: employed after disease progression on prior therapies.

• Irinotecan is converted in vivo to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex and stabilizes it. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage, replication arrest, and ultimately tumor cell death.

Irinotecan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Diarrhea: may be severe and require supportive care.
• Nausea and vomiting: typical chemotherapy‑related symptoms.
• Alopecia: hair loss during treatment cycles.
• Fatigue: generalized weakness and reduced stamina.
• Abdominal pain: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent medical attention.
• Severe colitis: life‑threatening inflammation of the colon.
• Allergic reactions: rash, itching, or anaphylaxis.
• Hepatotoxicity: liver enzyme elevations indicating potential liver injury.
• Pulmonary toxicity: rare lung inflammation or fibrosis.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Irinotecan requires careful monitoring and specific safety measures before and during therapy.

• Monitor blood counts: perform regular complete blood counts to detect neutropenia.
• Assess liver function: check hepatic enzymes and bilirubin prior to each cycle.
• Evaluate bowel status: screen for obstruction or severe diarrhea risk.
• Adjust dose in hepatic impairment: reduce dosage according to liver function tests.
• Avoid use in severe neutropenia: postpone treatment if neutrophils are critically low.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase SN‑38 exposure.
• UGT1A1 inhibitors (e.g., atazanavir, indinavir): raise risk of severe neutropenia.
• Concurrent myelosuppressive agents: additive bone‑marrow toxicity.
• Live vaccines: heightened infection risk during immunosuppression.
• Anticholinergic drugs: may exacerbate constipation and bowel complications.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic effect.
• Antacids containing magnesium or aluminum: may alter gastrointestinal absorption.
• Warfarin: monitor INR as irinotecan can affect anticoagulation control.